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The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl-selective anion channel expressed in epithelial tissues.Mutations in
CFTR lead to the genetic disease cystic fibrosis (CF). Within each epithelial cell, CFTR interacts with a large number of transient
macromolecular complexes, many of which are involved in the trafficking and targeting of CFTR. Understanding how these complexes regulate
the trafficking and fate of CFTR, provides a singular insight not only into the patho-physiology of cystic fibrosis, but also provides potential drug
targets to help cure this debilitating disease.
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Coordinated cellular responses to hormones or neuro-
transmitters depend not only on the presence of the ap-
propriate protein molecules within the cell, but also on the
appropriate location of those proteins within the cell. For⁎ Corresponding author. Tel.: +1 847 578 8362.
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doi:10.1016/j.jcf.2006.09.002many genetic diseases, point mutations (resulting in protein
sequence variants) lead not to a complete absence of the
affected protein, but rather the production of a “misfolded”
protein that fails to reach its appropriate location within the
cell [1,2]. Disease pathology resulting from such mutations
can result either from loss of protein and/or function at the
appropriate subcellular domain, or the deposition of “mis-
folded” aggregates in inappropriate locales. Aggregation of
“misfolded” proteins is observed in such diverse pathologicaled by Elsevier B.V. All rights reserved.
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diseases such as the spongiform encephalopathies and spe-
cific variants of α1-antitrypsin (α1-AT). In contrast, “loss-of-
targeting” pathologies are associated with diseases such as
retinitis pigmentosa, familial hypercholesterolaemia and
cystic fibrosis. In these latter cases, failure of the mutant
protein to fold appropriately is tightly associated with defects
in endoplasmic reticulum (ER) export competency, protein
trafficking and localization.
Cystic fibrosis (CF) (MIM 219700), the most common
life-threatening genetic disease of Caucasians [3] is caused by
mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR; ABCC7). This anion selective ion channel
is required for the normal function of epithelia lining the
airways, intestinal tract as well as ducts in the pancreas,
salivary and sweat glands. Characteristics of CF disease are
an exocrine pancreatic insufficiency, an increase in sweat
NaCl concentration and male infertility; however the major
cause of morbidity and mortality is pulmonary disease [4].
Although chronic inflammation and infection form a vicious
cycle leading to fibrosis and loss of lung function, there is
evidence of airway inflammation already present in CF
neonates [5,6]. The loss of CFTR from airway epithelial cells
also leads to altered regulation of other ion channels,
significant changes in the composition of airway surface
liquid (ASL) [7] and dysregulation of inflammatory elements
[8,9]. Over 1400 mutations have been identified in the CFTR
gene [10] (http://www.genet.sickkids.on.ca/cftr/), however
the most commonmutation is loss of a Phe residue at position
508 (ΔF508-CFTR). Approximately 70% of individuals with
CF are homozygous for the ΔF508-CFTR mutation, and
almost 90% of patients have at least oneΔF508-CFTR allele.
Based on the predominance of the ΔF508-CFTR mutation,
most of the basic research and drug-development initiatives
have focused on ΔF508-CFTR.
In the CFTR “life cycle”, there are four broad trafficking
pathways that can be identified (i) biosynthesis, conforma-
tional maturation and trafficking from the endoplasmic
reticulum (ER) to the plasma membrane, (ii) endocytic re-
trieval from the plasma membrane to early or sorting endo-
somes, (iii) recycling of endocytosed CFTR back to the cell
surface (either directly or via recycling endosomes) and (iv)
targeting of endocytosed CFTR for degradation (Fig. 1).
ΔF508-CFTR is recognized as misfolded by the ER quality
control machinery and targeted for proteosomal degradation
(Fig. 1(v)). Export of CFTR from the ER is dependent upon
the presence of both acidic and basic exit codes [11,12]. These
codes play a key role in linking CFTR to COPII-vesicles that
deliver newly synthesized CFTR to the Golgi apparatus [11],
prior to delivery of CFTR to the cell surface. Depending upon
the cell system investigated, anywhere from 60 to ∼100% of
wild-type CFTR folds appropriately in the ER and becomes
“export competent”, trafficking to the Golgi and cell surface
[13–15]. In contrast, the ΔF508 variant fails to fold properly
in the ER, is “ER export incompetent” and is rapidly degraded
by the ER quality control machinery and never reaches thecell surface [16–18]. Interestingly, early studies showed that
growth of ΔF508-CFTR expressing cells at reduced temper-
ature allowed the mutant CFTR molecules to exit the ER and
reach the cell surface [19]. This is possibly due to
temperature-dependent inefficiencies in the ER quality control
machinery rather than the acquisition of a “properly folded
conformation” by ΔF508-CFTR [20]. However, data to
formerly distinguish between a decrease in ER quality control
effectiveness or a possible increase in ΔF508-CFTR folding
efficiency when ΔF508-CFTR expressing cells are grown at
28 °C is not yet available. The search form pharmacological
agents that facilitate the exit of ΔF508-CFTR from the ER is
currently a major endeavour in both academic and pharma-
ceutical company laboratories, and of clear import in
developing potential therapeutic interventions in CF patients.
Although the biosynthetic trafficking of CFTR is an extremely
important field, the present reviewwill focus on the trafficking
of CFTR after it has reached the cell surface. Details of current
research on the biosynthetic trafficking of CFTR are available
in several excellent reviews [21–23].
2. Endocytic pathways
Endocytosis is classically thought of as a process whereby
nutrients and other molecules are taken up from the extra-
cellular milieu [24]. However, it is becoming increasingly
clear that endocytosis is also a key element in regulating the
cell surface density of a variety of integral membrane proteins,
including G-protein coupled receptors [25], receptor tyrosine
kinases [26], transport proteins [27] and ion channels [28–33].
Indeed, the number of ion channels whose cell surface ex-
pression, and hence cellular function is governed by endo-
cytosis and recycling has risen rapidly in the past few years.
Moreover, there is accumulating evidence that mutations that
alter the endocytic traffic of ion channels can have devastating
clinical consequences. For example Liddle's syndrome is
associated with reduced endocytic traffic of the epithelial
sodium channel (ENaC) leading to sodium hyperabsorption
[33,34], whereas mutations in ROMK1, a channel internalized
by clathrin mediated endocytosis [35], lead to Barter's syn-
drome [36], a salt-wasting disease. It is not surprising then, that
the cell surface density of CFTR is dependent upon endocytic
and recycling processes.
Although there are several endocytic mechanisms in cells
[37], the best characterized uses the coat protein clathrin
along with several accessory or adaptor proteins [37–39] to
internalize integral membrane proteins from the plasmalem-
ma. When clathrin coated vesicles (CCV) are isolated from
either epithelial cells grown in culture or native intact epi-
thelial tissues, large amounts of CFTR are seen to be present
[40]. Treatment of these CCV with coated vesicle “uncoa-
tase” to strip off the clathrin allows fusion of the resultant
vesicles (endosomes) with planar lipid bilayers (an electro-
physiological technique to study the biophysical properties of
isolated ion channels) leading to the incorporation of fully
active CFTR channels. In contrast, it is not possible to detect
Fig. 1. Model showing main trafficking pathways taken by wild-type and ΔF508-CFTR (i) CFTR is translated in the endoplasmic reticulum (ER) where core
sugars are added to the protein. MostΔF508-CFTR is recognized as misfolded by the ER quality control and targeted for proteosomal degradation (v). Wild-type
CFTR traffics to the Trans Golgi network where the core sugars are modified into complex carbohydrates, and then trafficked to the apical plasma membrane (i).
(ii) CFTR is efficiently removed from the cell surface by clathrin mediated endocytosis using trafficking signals embedded in the amino acid sequence of CFTR.
(iii) From endosomes, CFTR can recycle back to the cell surface in a direct manner, or via recycling endosomes. (iv) Internalized CFTR can be directed to
lysosomes for degradation.
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organelle [41–43]) purified from airway epithelial cells [44].
Interestingly when overexpressed in heterologous cell
systems, small amounts of CFTR can be detected in caveolae
[44]; likely an over expression artifact. Several tools are
available that differentially affect clathrin and caveolae me-
diated endocytic pathways. Exposure of cells to chlorprom-
azine, K+ depletion or hypertonic sucrose causes an
inhibition in clathrin mediated internalization [45] and a
marked reduction in CFTR endocytosis [29,44]. In contrast,
pharmacological agents that inhibit caveolae such as filipin,
and treatment of cells with extracellular cholesterol oxidase
[46] were unable to affect cell surface levels of CFTR. Taken
together, these data strongly argue that CFTR is removed
from the cell surface exclusively by clathrin mediated
pathways. Although it is not possible to exclude fully thepossibility of very low levels of CFTR entry into caveolae,
the data argue that if such caveolar CFTR exists, it is a minor
component of the total cell surface CFTR pool. However, it
should be noted that recently Kowalski and Pier [47] argued
that entry of CFTR into caveolae is critical for its function as a
cellular receptor for Psuedomonas aeruginosa [48]. These
authors proposed that Pseudomonas-dependent entry of
CFTR into caveolae triggers the internalization of a CFTR/
Pseduomonas complex. Data presented in support of this
hypothesis was based upon finding CFTR and caveolin-1 (a
marker for caveolae) in similar fractions when Triton X-100
insoluble pellets were subject to a sucrose density gradient
centrifugation protocol. However, such data merely indicates
similar buoyant densities of the CFTR and caveolin-1
fractions, not necessarily co-localization within the same
vesicle.
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Whilst no-one would question that CFTR would be re-
moved from the plasma membrane at some point during its
life cycle, when early studies on CFTR endocytosis were
performed it was surprising how rapidly CFTR was removed
from the cell surface. Using a cell-surface biotinylation
approach, Prince et al. demonstrated that CFTR was
efficiently removed from the apical membrane of polarized
epithelial cells [49], with 25% of cell surface CFTR being
internalized in 2.5 min; an uptake rate significantly greater
than non-specific bulk uptake of other surface glycoproteins
[49]. In general, CFTR appears to be removed from the cell
surface with rates not dissimilar from that of nutrient and
signal molecule receptors, proteins typically associated with
efficient clathrin mediated endocytosis. Such efficient
endocytosis through clathrin mediated pathways argues for
the presence of internalization motifs within CFTR. A
complete review of endocytic signals is beyond the scope
of this review; for a more in-depth analysis of sorting motifs,
the reader is directed to a number of excellent review articles
[38,50–54]. Briefly, endocytic sorting signals are generally
short linear arrays of amino acids in the cytoplasmic domains
of integral membrane proteins that, although not entirely
conserved between proteins, are usually four to seven amino
acids in length of which two to three are critical for function.
The critical amino acids are usually bulky and hydrophobic.
Two major classes of endocytic signal have been character-
ized, “tyrosine-based” and “dileucine-based” depending
upon which are the critical amino acids in the motif.
Tyrosine-based motifs come in two flavours, NPXY where
X is a variable amino acid, and YXXΦ where Φ is a bulky
hydrophobic amino acid. The NPXYendocytic signal was the
first to be identified by Goldstein et al. in the LDL receptor,
[55] for which they won the 1985 Nobel prize in Medicine,
yet this is a fairly rare motif and the more common sequence
is the YXXΦ sequence. For other membrane proteins, di-
leucine motifs (D/EXXXLL/I and DXXLL) are important for
targeting proteins that bear them (e.g., LIMP11 and CD3-γ)
to endosomal/lysosomal compartments [56].
Taking a chimeric approach, Prince and colleagues gen-
erated proteins containing the extracellular and transmem-
brane domains of the transferrin receptor fused to either the
amino or carboxyl cytoplasmic domains of CFTR [31]. In this
context, both the amino and carboxyl terminal domains of
CFTR were sufficient to direct efficiently the internalization
of the fusion proteins from the cell surface. Using a similar
chimeric approach in which domains of CFTR were fused to
the interleukin 2 receptor α-chain (Tac) [57], Hu et al. also
demonstrated that the carboxyl terminal domain of CFTR
contained sequences sufficient for efficient endocytosis of the
resultant chimeras. Although the amino terminal domain was
able to promote endocytosis of transferrin receptor chimeras,
it has been difficult to demonstrate such a role within the
context of intact full-length CFTR, since mutation of this
region results in a misfolded protein that fails to reach the cellsurface. Therefore, precisely what role the amino terminus
plays in CFTR endocytosis remains unclear. Moreover, the
issue of whether the amino terminus of CFTR plays a role in
endocytic trafficking is complicated by the evidence that this
region of CFTR also interacts with other components of the
intracellular trafficking machinery, where syntaxin/CFTR
interactions modulate CFTR movement and/or channel ac-
tivity [58–61]. If the interaction between the amino terminus
of CFTR and syntaxins is necessary for physiological
regulation of CFTR channel activity at the cell surface, an
intriguing possibility is that regulated syntaxin/CFTR inter-
actions would prevent the interaction of CFTR's amino
terminus with the clathrin/adaptor endocytic machinery
increasing the residence of CFTR at the cell surface. Despite
the uncertainty of the role of the amino terminus of CFTR in
modulating CFTR endocytosis, a clear consensus on the role
of the carboxyl terminus of CFTR in endocytic trafficking has
emerged.
Comparison of the amino acid sequences of CFTR
carboxyl-termini from various species reveals the presence
of a conserved tyrosine-based (YXXφ motif) (Table 1).
Mutational analysis in both CFTR chimeras and intact CFTR
constructs confirms that 1424YDSI is an authentic tyrosine
internalization motif [31,57,62]. Interestingly, both dog
(Canis familiaris) and dogfish (Squalus acanthus) have a
phenylalanine residue rather than tyrosine at the equivalent
position to Y1424 in human CFTR. Phenylalanine residues
are able to substitute for tyrosine residues and maintain wild-
type internalization activity of the transferrin receptor [63],
and mutation of tyrosine to phenylalanine within the context
of human CFTR does not inhibit CFTR endocytosis [64],
arguing that the endocytic signal is intact in dog and dogfish.
Whether or not there are subtle differences in CFTR traf-
ficking kinetics for proteins bearing a Phe residue compared
to a Tyr residue at position 1424 are not known.
Fusing segments of CFTR with a truncated interleukin 2
receptorα chain (TacT) [57], Hu et al. argued for the presence
of three endocytic motifs in the carboxyl terminus of CFTR; a
phenylalanine-based motif (1413FLVI), the previously iden-
tified tyrosine-based motif (1424YDSI) and a di-leucine based
motif (1430LL).Whilst the Phe-basedmotif was not addressed
by Collawn et al., their transferrin receptor chimeras also
identified a potential di-leucine based motif at 1430LL [31].
Mutation of either the tyrosine motif alone 1424YDSI→
ADSI or the di-leucine motif alone 1430LL→AL results in
similar levels of inhibition in CFTR endocytosis (66% and
61% respectively) [57]. Interestingly, in these studies,
inhibition of CFTR endocytosis did not lead to increases in
macroscopic analysis of halide efflux [57]. It is possible that
macroscopic assays such as iodide efflux assays are not
sensitive enough to allow correlations between changes in
cell surface density and channel function, therefore further
assays such as whole cell patch clamping likely will be
needed to address this issue. As with mutations in putative
endocytic motifs in the amino terminus of CFTR, mutation of
the Phe based signal (1413FLVI) also results in a protein that
Table 1
Comparison of the amino acid sequences of various CFTR carboxyl-terminal tails
Human AFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQAISPSDRVKLFP
HRNSSKCKSK PQIAALKEETEEEVQDTRL
Orangutan AFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFQQAISPSDRVKLFP
HRNSSKCKSK PQIAALKEETEEEVQDTRL
Macaque AFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQAISPSDRVKLFP HRNSSKCKTQ
PQIAALKEETEEEVQDTRL
Lemur AFADCTVILCEHRIEAMLECQRFLVIEENNVRQYDSIQKLLSEKSLFRQAISPSDRMKLFP RRNSSKHKSR PPITALK
EETEEEVQDTRL
Dusky AFADCTVILCEHRIEAMLECQQFLVIEENKVEQYDSIQKLLNEKSLFQQAISHSDRVKLFP HRNSS
KYKSR PQIASLKEETEEEVQETRL
Horse AFADCTVILSEHRIEAMLECQRFLVIEENKVRQYDSIQKLLSEKSLFQQAISSSDPLKLFP HRNSSKHKSR SKIAALQEETEEEVQETRL
Cow AFANCTVILSEHRIEAMLECQRFFVIEENKVRQYDSIQRMLSEKSLFRQAISPADRLKLLP
HRNSSRQRSR SNIAALKEETEEEVQETKL
Pig AFADCTVILSEHRIEAMLECQRFLVIEENKVRQYDSIQRLLSEKSLFRQAISPLDRLKLLP HRNSSKQRSR SKIAALKEETEEEVQETRL
Sheep AFADCTVILSEHRIEAMLECQRFLVIEENKVRQYDSIQRMLSEKSLFRQAISPADRLKLLP
HRNSSRQRSR ANIAALKEETEEEVQETKL
Rabbit AFADCTVILCEHRIEAMLECQRFLVIEENTVRQYDSIQKLLSEKSLFRQAISSSDRAKLFP HRNSSKHKSR PQITALKEEAEEEVQGTRL
Mouse AFAGCTVILCEHRIEAMLDCQRFLVIEESNVWQYDSIQALLSEKSIFQQAISSSEKMRFFQ
GRHSSKHKPR TQITALKEETEEEVQETRL
Rat AFAGCTVVLCEHRIEAMLDCQRFLVIEQGNVWQYDSIQALLSEKSVFQRALSSSEKMKLFH GRHSSKQKPR
TQITAVKEETEEEVQETRL
Xenopus AFADCTVILSEHRLEAMLECQRFLVIEDNTVRQYDSIQKLVNEKSFFKQAISHSDRLKLFPLHRRNSSKRKSR
PQISALQEEQEEEVQDTRL
Killifish SFSGCTVILSEHKVEPLLECQSFLVIEKSSVRQYDSIQKLMNEMSHLKQAISPADRLHLFPTPHRLNSIKRPQPQTTKISALQ
EETEEEVQDTRL
Dog AFADCTVILSEHRIEAMLECQRFLVIEDSRLRQFESIQRLLSERSAFRQAUGPPERPGLL PHRLSSRQRSP SRIAALKEETEDEVQDTRL
Dogfish TFSNCTVILSEHRVEAILECQSFLVIEGCSVKQFDALQKLLTEASLFKQVFGHLDRAKLFTAHR
RNSSKRKTR PKISALQEEAEEDLQETRL
Amino acid sequence alignment of carboxyl tails of CFTR from human (P13569), orangutan (Q2QL83), macaque (Q9TUQ2), lemur (Q2Ql83), dusky titi
(Q2QLB4), horse (Q2QLA3), cow (P35071), pig (Q6PQ22), sheep (U20418), rabbit (Q00554), mouse (M60493), rat (1901178A), Xenopus (U60209), killifish
(AF000271), dog (Q5U820) and dogfish (P26362).
All sequences except dog and dogfish conform to the YXXΦ motif common to internalization signals, where X can be any amino acid and Φ is a hydrophobic
residue.
Phenylalanine has been shown to substitute for tyrosine and still maintain wild-type internalization of CFTR [64] and the transferrin receptor [63].
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thus evaluation of 1413FLVI is not possible. The failure of
1413FLVI mutations to properly mature is likely due to the
location of 1413F at the boundary between NBD-2 and the
carboxyl terminus of CFTR. Studies by Gentzsch et al. [65]
argue that a hydrophobic patch 1413FLVI is necessary for the
structure and stability of NBD-2; the same sequence that was
suggested to be an internalization motif based on chimera
studies [57]. Since endocytic sequences need to be exposed to
the cytosol in order to interact with the endocytic machinery,
it is not clear how a hydrophobic patch within the context of
intact CFTR would fulfill the role of both a domain stabilizer
and an internalization motif. Thus it is possible that the
identification of 1413F as an internalization sequencemay be a
chimeric artifact. Based on structural considerations, homol-
ogy with NBD-1 and homology with NBDs from other ABC
transporters, Gentzsch et al. have argued that theβ-strand that
delineates the last structural element of NBD-2 terminates at
amino acid 1424tyr [65]. Crystal structures of the μ2 clathrin
adaptor subunit complexed with the endocytic motifs of the
EGF receptor and the Golgi protein TGN38 show that the
endocytic motif adopts an extended β-strand conformation
[66], and that the tyrosine residue cannot be present in a β-turn. Definitive answers to the structure of the 1424YDSI
internalization motif and the boundary of NBD-2 thus await
future crystallization studies.
3.1. Are there any clinical mutations in endocytic signals?
There are no known point mutations in the endocytic
signals of CFTR, however there are premature stop codons
that give rise to molecules lacking that region of CFTR
containing internalization motifs [67]. While such molecules
are apparently biosynthetically normal, the mature fully gly-
cosylated molecules are very unstable and are substrates for
proteosome-dependent degradation [68]. Thus, the impor-
tance of inhibiting CFTR endocytosis in the context of a
patient cannot be determined. However, given the role of
unregulated CFTR activity in toxigenic secretory diarrhea,
one may anticipate that chronic loss of CFTR endocytosis (in
the absence of any other compensatory mechanisms) would
lead to some degree of pathologic intestinal fluid loss. In the
absence of identified clinical mutations in endocytic
sequences it is thus not possible to study ‘loss of endocytosis
motif’mutations in a patient setting. Nevertheless the effects
of artificial point mutations in cell lines can and have been
6 N. Ameen et al. / Journal of Cystic Fibrosis 6 (2007) 1–14studied. For example the effects of a mutation that results in
the gain of an endocytosis signal have been described [69]. A
patient with a mutation N287Y (991A→T) was identified
based on a diagnosis of elevated sweat electrolytes [70].
Clinically, the patient presented as pancreatic sufficient, but
did have 4–5 upper respiratory tract infections per year. Thus
the patient can be considered to have a mild CF phenotype.
Biosynthesis and delivery of N287Y CFTR to the cell surface
is unaffected, but endocytosis of N287Y CFTR from the cell
surface is markedly enhanced (∼ twice the rate of wild-type
CFTR), resulting in a 50% reduction in steady-state levels of
CFTR at the cell surface. In contrast to many mutations in
CFTR, the single channel properties of N287Y CFTR and
wild-type CFTR are indistinguishable arguing that disease
cannot be attributed to conductance or gating defects, but
rather to enhanced CFTR endocytosis. The genotype of the
identified patient was ΔF508/N287Y [70]. Since little or no
cell surface CFTR is produced by the ΔF508 allele, the only
CFTR protein is produced from the N287Yallele, this would
potentially lead to a 75% reduction in the amount of CFTR at
the cell surface compared with individuals homozygous for
wild-type CFTR. Such data would argue that at least 25% of
wild-type CFTR activity is required to ameliorate the disease
symptoms in CF patients. It is of interest to note that the
N287Ymutation is a gain of function mutation and appears to
generate an endocytic signal that is present within the body of
the protein rather than at the termini of the protein, a location
not previously identified in polytopic membrane proteins. In
the broader context of molecular mechanisms underlying the
pathology of human genetic diseases, the significance of the
observations on N287Y CFTR lies in the recognition that
mutations can reduce the expression level of a membrane
protein, not only by impairing its biosynthesis or stability (or
in the case of ion channels their biophysical fingerprint), but
also by accelerating endocytic retrieval from the plasma
membrane.
R31C and R31L are CFTR mutations that also give rise to
a mild clinical phenotype [71]. Both of these mutations
generate a CFTR molecule that has dramatically enhanced
endocytic rates [72]. Precisely why these mutations affect
endocytosis is not clear, however it is possible that they
introduce a hydrophobic residue relative to an upstream
tyrosine Y, Y28XXC31 and Y28XXL31, or that such mutations
somehow affect the recognition of the tyrosine-based motif in
the carboxyl terminus to enhance endocytosis. Expression of
R31C and R31L CFTR leads to reduced macroscopic
currents compared to expression of wt CFTR; however,
since single channel records were not determined it is not
possible to determine whether the reduced macroscopic
currents are due to endocytic defects alone, or whether there
are also altered gating kinetics.
3.2. Recycling of CFTR
Many membrane transport proteins are rapidly recycled
between intracellular vesicles and the cell surface, whereasothers have a long residence on the plasma membrane.
Recycling of membrane proteins serves several functions, (i)
it allows receptors to internalize ligands, such as nutrients,
hormones and toxins, (ii) recycling also allows cells to
regulate the steady-state levels of proteins by altering the
relative rates of endocytosis and exocytosis and (iii)
recycling of membrane proteins also protects them from
degradation and allows them to undergo multiple rounds of
endocytosis and recycling. For example, the kidney collect-
ing duct recycles the aquaporin water channel AQP2
between intracellular vesicles and the cell surface in response
to vasopressin [73–75], and Glut4 glucose transporters
recycle between endosomes/recycling vesicles and the cell
surface in response to insulin [76–78]. Endocytosed material
is initially directed to an endosomal sorting compartment
from which it is directed to one of two destinations (see
Fig. 2). Some molecules, such as low-density lipoprotein
(LDL) are retained in the sorting endosomes that mature into
and/or fuse with late endosomes and lysosomes for
degradation [79]. Molecules that are destined to be recycled
back to the cell surface are initially targeted to the endosomal
recycling compartment (ERC) [80].
Given that endocytic internalization kinetics for CFTR
are rapid [29,49,64] and that internalized CFTR is fully
functional [81], the argument can be made that internalized
CFTR is likely recycled back to the cell surface. Indeed,
given the rapid internalization kinetics of CFTR, biosyn-
thetic kinetics would have to be equally rapid to maintain
steady state surface CFTR were all internalized CFTR to be
degraded. However, treatment of CFTR expressing CHO
cells with either cycloheximide or brefeldin A does not cause
any diminution of forskolin-stimulated CFTR currents up to
24 h [82]. Similarly, our laboratory has also shown that
forskolin-stimulated CFTR currents are maintained in
polarized T84 epithelial monolayers at least 24 h after
cycloheximide-dependent arrest of CFTR biosynthesis
(unpublished observations). Lack of effect of biosynthetic
inhibitors on CFTR mediated Cl secretion in the background
of rapid CFTR endocytosis strongly argues that internalized
CFTR is indeed recycled back to the cell surface. Using a cell
surface biotinylation approach [62], our lab, and that of
Swiatecka-Urban and colleagues, have shown that internal-
ized CFTR is very efficiently recycled back to the cell
surface with approximately 50% of internalized CFTR being
recycled back to the cell surface [83,84]. Similarly, Sharma
and colleagues used an extracellular epitope tagged CFTR
construct to clearly show that CFTR entering the early
endosomal compartment is targeted for recycling back to the
cell surface [85].
Whilst there is compelling evidence that CFTR channels
undergo endocytic recycling, such is not the case for all ion
channels. For example, once inserted into the cell surface, the
inwardly rectifying potassium channel Kir3.4 is a stable
component of the plasma membrane and when it does un-
dergo endocytosis is degraded rather than recycled [30]. Why
CFTR should undergo such rapid internalization and
Fig. 2. Model showing involvement of various proteins in CFTR endocytosis and recycling CFTR (brown rectangle) is endocytosed from the apical plasma
membrane in a clathrin dependent process that requires dynamin (for vesicle fission), the μ subunit of the AP-2 adaptor complex that mediates interaction
between the YDSI endocytic motif on CFTR and the clathrin lattice. The endocytosis of CFTR also requires myosin-VI, a molecular motor that drives cargo to
the minus end of F-actin (i.e., inwardly directed). Several members of the RabGTPase family have been shown to modulate CFTR trafficking. Rab5 promotes
endocytosis of CFTR. Exit of CFTR from early endosomes can be mediated by Rab4 which directly targets CFTR back to the plasma membrane, or by Rab7
which increases CFTR degradation by enhancing the trafficking of CFTR to late endosomes and lysosomes. Rab9 mediates CFTR trafficking from late
endosomes to the transGolgi network (TGN). Rab11 mediates CFTR trafficking from recycling endosomes to either the plasma membrane or to the TGN. RME-
1 facilitates exit of CFTR from the recycling endosome. PDZ binding proteins can inhibit CFTR endocytosis from the plasma membrane, as well as facilitate
recycling of internalized CFTR from early endosomes.
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porters, regulation of cell surface density and “gating” of
resident transporters may be complementary modes of
regulation. Indeed, given the pathological extremes observed
with CFTR hyperactivity (as seen in toxin induced secretory
diarrheas) and CFTR hypoactivity (as seen in cystic fibrosis),
it is clear that CFTR protein/function has to be maintained
within a very narrow window of activity. Another intriguing
possibility underlying the physiological role of CFTR re-
cycling arises from the notion that CFTRmay take an unusual
route from the ER to the cell surface. Balch and colleagues
[86,87] have argued that CFTR takes a non-conventional
route from the ER to the Golgi. Thus in BHK and CHO cells,
but not HeLa and 293T cells, CFTR is initially targeted
directly from the endoplasmic reticulum to the late Golgi/
endosomal compartment without traversing the medial or cis
Golgi compartments. Acquisition of a mature fully glycosy-
lated status would thus require recycling of CFTR through a
late Golgi/endosomal system.3.3. Regulated CFTR trafficking
In addition to undergoing constitutive endocytic recycling
[83,85,88,89], there is strong evidence that CFTR undergoes
regulated trafficking between intracellular compartments and
the cell surface [88]. Acute regulation of CFTR insertion into
and endocytosis from the plasma membrane is mediated by
the cAMP-dependent protein kinase (PKA) [27–29,31,88,
90–92]. The overall flow of ions across a membrane (as-
suming no other limiting factors) is governed by the equation
I= iNPo, where I is the macroscopic current, i is the unitary
conductance of the channel (in this case CFTR), N is the
number of channel in the plasma membrane and Po is the
open probability of the channel. It is therefore theoretically
possible that a secretagogue could alter ion flow across a
membrane by altering i, N or Po. In practice, i is rarely
altered, leaving changes in N and/or Po to account for
changes in transmembrane ion flow. When secretagogues
stimulate Cl secretion through the cAMP/PKA mediated
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activation of cell surface resident CFTR mediated by R-
domain phosphorylation (increase in Po), and secondly there
is a trafficking of CFTR from intracellular storage vesicles
into the plasma membrane (increase in N). Interestingly, in
some cell types, the ability of PKA to regulate CFTR
trafficking depends upon the expression of wild-type CFTR.
In cells from patients with cystic fibrosis, PKA fails to alter
endocytosis [93].
In order to undergo regulated trafficking to the plasma
membrane two critical requirements for CFTR must be
fulfilled: the first is that CFTR is present in and stored in
organelles beneath the plasma membrane and secondly, those
storage vesicles should mobilize rapidly or translocate to the
plasma membrane for insertion upon appropriate secreta-
gogue or second messenger stimulation. Once in the plasma
membrane, the newly inserted CFTR proteins (which may be
intrinsically active or require activation in the plasma mem-
brane) contribute to the overall chloride transport of the
plasma membrane [27]. The initial suggestion that CFTR
may undergo regulated trafficking arose from observations
based on morphologic studies characterizing the subcellular
distribution of CFTR in a number of epithelial tissues. Though
CFTR was recognized to be an apical membrane chloride
channel, immunofluorescence localization studies of a variety
of epithelial tissues suggested that in addition to its presence on
the apical plasma membrane, CFTR could be detected in the
sub apical cytoplasm in a punctate distribution, suggesting its
location in a vesicular storage pool beneath the plasma mem-
brane [94–96]. Despite the suggestive immunofluorescence
data, the precise subcellular localization for CFTR requires the
use of electron microscopic techniques since fluorescence
localization lacks the sensitivity to discriminate between
CFTR that is localized to sub apical vesicles in close proximity
(less than 100 nm) to the apical membrane, and CFTR present
in the apical membrane. Immunoelectron microscopic local-
ization is the most sensitive method to distinguish clearly
CFTR on the plasma membranes from that in vesicles. Sadly,
few studies have localized successfully CFTR by immunoe-
lectron microscopy because (i) CFTR is a low abundance
protein in most cells (ii) its detection in tissues and cells is
dependent on the use of high affinity specific antibodies (iii) its
detection is sensitive to routine methods used for fixation and
preparation of samples for electron microscopy (iv) the tech-
nique is labour intensive, expensive, and usually successful
only in very experienced centres.
Nevertheless, successful characterization of the subcellu-
lar distribution of CFTR by immunoelectron microscopy has
been accomplished in two endogenous CFTR expressing
tissues that express high levels of CFTR, using well char-
acterized high affinity antibodies [87,91,97]. Pools of endo-
somal CFTR have been documented by electron microscopic
localization in the sub apical cytoplasm of rat submandibular
glands, that co-localized with markers of receptor mediated
endocytosis, confirming that CFTR undergoes receptor
mediated endocytosis in that tissue [97]. We used cryoim-munoelectron microscopy to examine the subcellular distri-
bution of CFTR in rat intestinal tissues. We confirmed that
CFTR was present on the membranes of the apical microvilli
and on the membranes of sub apical vesicles within crypt
cells. Quantitative analysis of the subcellular distribution of
CFTR by immunogold labeling revealed that CFTR was
equally distributed between the apical plasma membrane and
intracellular vesicles in crypt cells, a distribution that was
consistent with its role in regulated trafficking. This dis-
tribution suggested that like other solute transporters that
regulate ion transport by regulated trafficking, cAMP-
dependent CFTR mediated chloride and fluid secretion in
the crypt may be regulated by acute insertion of cytoplasmic
vesicles into the apical plasma membrane. This was con-
firmed in a recent study in rat small intestine. Intravenous
administration of vasoactive intestinal peptide (a potent
physiologic cAMP agonist) to rats resulted in an acute re-
distribution of CFTR to the apical surface of crypt enterocytes
that was associated with fluid secretion [98].
Although there is compelling evidence for PKA-depen-
dent trafficking of CFTR in intestinal cells, there is no direct
evidence for such trafficking of CFTR in airway epithelial
cells [88,99,100]. In fact, direct measurements of CFTR in
the plasma membrane of airway epithelial cells show no
change in CFTR levels upon PKA stimulation [99,100]. Why
should there be a difference in CFTR trafficking patterns
between intestinal and airway epithelial cells? It is possible,
even probable, that the proteins which interact with and
regulate CFTR activity and trafficking display cell-type
specificity. Thus the complement of proteins necessary to
impart PKA sensitivity to CFTR traffickingmay be expressed
in intestinal but not airway cells. The difference between
PKA dependent CFTR trafficking in airway and intestinal
cell may also reflect a fundamental difference in the phys-
iology of airway and intestinal epithelial tissues. Although
Cl− is the dominant ion passed through CFTR in intestinal
cells, there is a strong argument that CFTR may pass bi-
carbonate (HCO3
−) in airway cells [101,102]. For a more
comprehensive discussion on regulated trafficking of CFTR
and epithelial secretion, the reader is directed to an excellent
comprehensive review on this topic [88].
3.4. GTPases, myosin-VI and PDZ sequences modulate
CFTR trafficking
Several molecules are now known to regulate vesicular
trafficking through the endosomal and recycling compart-
ments, including Rabs, Rme-1 and myosins [80,103–112].
Rab GTPases are molecular switches that have several
cellular functions, including cargo selection during vesicle
transport, tethering of vesicles to motor proteins, and fa-
cilitating vesicle docking and fusion [113]. Several Rab
GTPases have been shown to modulate the intracellular
trafficking of CFTR [89,114] (Fig. 2). Rab5 facilitates the
trafficking of CFTR from the cell surface to early endosomes,
whereas Rab11 controls trafficking of CFTR from early
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ficking of endocytosed CFTR back to the cell surface. Rab7
regulates movement of CFTR from early endosomes to late
endosomes and from late endosomes to lysosomes. Alterna-
tively, CFTR in late endosomes can undergo Rab9-dependent
trafficking to the TGN and thence back to the cell surface.
Given the importance of Rabs in regulating CFTR trafficking,
it is not surprising that manipulation of Rab activity can be
used to alter the cell surface levels of both wt and ΔF508-
CFTR [89,114]. Indeed, it is possible that Rab GTPases may
be potential therapeutic targets for treating CF.
Rme-1 is a GTPase that regulates exit from the endosomal
recycling compartment (ERC). Rme-1 plays no role in
endocytosis, or in trafficking of material from early en-
dosomes to lysosomes. A mutation near the EH domain of
RME-1 (G429R) has a dominant-negative phenotype and
causes the protein to associate tightly with the ERC, pre-
venting exit but not entry of endocytosed material into the
ERC. Trafficking of material such as LDL from the cell
surface to early endosomes to lysosomes is unaffected by
G429R Rme-1, since such trafficking bypasses the recycling
pathway. For molecules, such as transferrin, that recycle,
G429R Rme-1 has no impact upon endocytosis, transport to
early endosomes or transport into the ERC; yet once in the
ERC the exit of molecules such as transferrin is blocked
leading to an accumulation in, and an expansion of, the ERC
[80,110]. Expression of G429R Rme-1 has no effect on
CFTR endocytosis, which continues uninterrupted. However
when endocytosed CFTR enters the recycling compartment,
it is trapped and cannot exit back to the cell surface. The block
in recycling without a block in endocytosis of CFTR leads to
a marked steady-state redistribution of CFTR such that
almost no CFTR is present in the cell surface, and the
majority of CFTR is trapped in an expanded ERC [83]. This
redistribution of CFTR away from the cell surface to re-
cycling compartments in the presence of G429R Rme-1
argues that maintenance of steady-state cell surface levels of
CFTR is primarily due to recycling of internalized CFTR
rather than insertion of newly synthesized CFTR.
Myosin motors are a large superfamily of proteins that use
the energy from ATP hydrolysis to move themselves (and
vesicles bound to them) along actin filaments [112,115].
Myosin VI is distinct from other myosins, in that it moves the
cargo towards the F-actin minus end (i.e., away from the
plasma membrane into the cell), a direction consistent with a
role in endocytosis [116,117]. Expression of the tail domain of
myosin VI, a dominant negative recombinant fragment that
retains cargo binding ability but no motor head domain,
increases the expression of CFTR at the plasma membrane, by
inhibiting endocytosis of CFTR.Consistent with its function in
endocytic traffic, tail domains of myosin VI have no effect on
the recycling of CFTR back to the cell surface [118].
PDZ domains are a common module found in mammalian
proteins [119–121]. PDZ domains are 80–100 amino acid
sequences that mediate protein–protein interactions by
binding to short peptide sequences that are often, but notalways, at the carboxyl termini of proteins. In this way, PDZ
proteins are able to form macromolecular complexes, cluster
and colocalize transport proteins, channels and signaling
molecules in specific subcellular domains, and modulate
protein trafficking. The carboxyl terminus of CFTR contains
a PDZ domain binding motif (DTRL) that plays several
potential roles in CFTR trafficking. NHERF-1 (also known
as EBP50), NHERF-2, NHERF-3 (also known as CAP70),
NHERF-4 and CAL (CFTR associated ligand) are all able to
bind the DTRL motif on CFTR. NHERF-1 and 2 also
possess regions that allow them not only to interact with
CFTR, but also with the apical actin cytoskeleton. Such
interactions may tether CFTR in a stabilized network in
specific apical compartments, preventing its removal from
the cell surface by clathrin mediated endocytosis. Since PDZ
proteins are also able to target PKA to macromolecular
complexes with CFTR [122], such interactions may facilitate
the PKA dependent inhibition of CFTR internalization as
well as PKA dependent activation of CFTR's ion channel
activity. NHERF-1 possesses two PDZ domains, leading to
the speculation that NHERF-1 may facilitate CFTR
dimerization [123,124]. Moreover, dimerization of CFTR
has been suggested to be dependent upon PKA activation
[125]. Although the dimerization of CFTR is still contro-
versial [126], an intriguing model has been suggested, in
which dimerization of CFTR may prevent its endocytic
retrieval from the cell surface, leading to an increase in the
number of CFTR molecules on the cell surface. The model
further proposes that PKA activation would lead to a
dimerization of CFTR (inhibiting its endocytosis) and an
activation of CFTR channel activity at the cell surface [126],
consistent with the observations that PKA reduces the
endocytosis of CFTR from the plasma membrane [29,49].
Following PKA inactivation, dephosphorylation of CFTR
would lead to channel inactivation, and a switch from
dimeric to monomeric CFTR would then lead to a loss of
CFTR protein from the cell surface by allowing monomeric
CFTR to be removed by endocytosis.
There is also some evidence that the PDZ binding domain
of CFTR plays a role in CFTR recycling. Removal of the last
3 amino acids of CFTR (CFTR-ΔTRL) causes a reduction of
cell surface stability of the resultant protein, not by altering
endocytosis but rather by reducing the ability of the CFTR-
ÄTRL molecule to recycle [84]. Whether the loss of the PDZ
binding domain leads to a decreased ability of CFTR-ΔTRL
to enter the recycling pathway or to an increased ability of
CFTR-ÄTRL to enter a degradative pathway is not known. In
addition, what PDZ proteins CFTR interacts with to undergo
endocytic recycling are not known. Interestingly, the PDZ
binding domain of CFTR appears to be a self-contained
recycling element, and is able to function as a transplantable
signal to facilitate the efficient recycling of G-protein coupled
receptors to which it is appended [127]. For a detailed de-
scription of the role of macromolecular complexes in reg-
ulating CFTR trafficking through the biosynthetic pathway,
and the regulation of CFTR activity at the cell surface, the
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Stanton [119].
3.5. Recycling of ΔF508-CFTR
Given the low levels ofΔF508 in the plasma membrane of
cells grown at 37 °C (but see also Ref. [128]) it has been
difficult to perform trafficking assays on ΔF508-CFTR.
Experimentally, the most robust means of increasing the
cell surface expression of ΔF508-CFTR has been to grow
cells at reduced temperature [19], so-called ‘temperature-
rescued’ ΔF508-CFTR. Clues to the endocytic trafficking of
‘temperature-rescued’ ΔF508-CFTR first came from studies
by Heda et al. [129] who showed a markedly reduced cell
surface stability of ΔF508 compared to wt CFTR. Later
quantitative studies showed that there was almost a 10-fold
decrease in the surface half life of mutant CFTR [85]. Such a
decrease could be due to accelerated internalization, reduced
recycling and/or targeting of endocytosed CFTR to degrada-
tion. Sharma and colleagues showed that the endocytic rate
constant for ΔF508-CFTR was not significantly different
from that of wt CFTR [85], arguing for abnormalities in
ΔF508 recycling. Internalized ΔF508 did not enter the
recycling compartment, but rather was “tagged” as misfolded
in the sorting endosome by the addition of ubiquitin and
targeted for lysosomal degradation. In contrast to the studies
of Sharma, those of Swiatecka-Urban and colleagues argue
that the cell surface stability of ΔF508-CFTR is reduced due
to accelerated endocytosis from the cell surface, with no
alteration in endocytic recycling [89]. The molecular
mechanisms whereby ΔF508 undergoes enhanced endocy-
tosis were not elaborated in these studies. The basis for the
disparity in the mechanisms underlying the reduced cell
surface stability of ‘temperature-rescued’ ΔF508, decreased
recycling vs. increased endocytosis, is not entirely clear.
Although both studies used over expression of ΔF508 in
epithelial cells, different cell types were employed. Studies
using Panc-1 cells (a pancreatic duct cell line) [85] showed
ΔF508 endocytosis to be normal and recycling abnormal,
whereas studies CFBE41o− cells (an airway epithelial cell)
showedΔF508 endocytosis to be enhanced [89]. In addition,
different methodologies were used to monitor CFTR
recycling (epitope-tagged CFTR [85] and cell surface
biotinylation [89]). Thus, while there is general agreement
on the observation that the cell surface stability of ΔF508 is
significantly reduced compared to wtCFTR, the precise
mechanisms responsible for this reduction are far from clear.
3.6. Future directions
Given that CFTR is an integral membrane protein, one can
easily assert that CFTR is obliged to traffic through the cell
within membrane limited organelles. We are beginning to
understand the compartments through which CFTR traverses
on its way into, and out of the plasmamembrane as well as the
molecules which play a role in mediating the entry and exit ofCFTR between these compartments. However, it is likely that
we have underestimated the complexity and the number of
proteins involved in CFTR trafficking. For example, many of
the studies on CFTR trafficking have been performed in
heterologous expression systems, and it is now critical to
move such studies forward into fully polarized epithelial cells
such as airway, intestine and exocrine pancreas cells that are
affected by cystic fibrosis. A thorough understanding of how
CFTR traffics within its native environment is essential to
identifying potential therapeutic targets for cystic fibrosis
therapy. Indeed, it is also important to understand how
mutations in CFTR affect its trafficking. A large amount of
time, effort and money is being focused on pharmacological
strategies to increase the exit of ΔF508-CFTR from the ER
and its subsequent insertion into the plasma membrane.
Given the present review, such an approach is clearly only
half the therapeutic battle in maintaining mutant CFTR at the
plasma membrane. The question of how much “correction”
ΔF508 needs to achieve in order to cure cystic fibrosis is one
that is central to drug development, and will become in-
creasingly important as we move into clinical trials. Under-
lying the question of “how much ΔF508 correction do we
need?” is the complication of what it is that needs correcting
inΔF508.ΔF508 has a folding problem in the ER, leading to
its degradation rather than export to the Golgi. Since the
phenylalanine residue at position 508 will always be missing
(absent gene therapy), ΔF508-CFTR can never fully achieve
a wild-type conformation. The question then is how close an
approximation of wild-type CFTR structure can ΔF508
attain? The answer to that question lies in what physiological
role 508Phe plays. Although it has been proposed that 508Phe
is involved in intramolecular domain–domain interactions,
there is still no definitive evidence in support of this. In
heterologous expression systems, the efficiency with which
wild-type CFTR is exported from the ER is ca. 60%. If the
export efficiency of ΔF508-CFTR is ca. 1%, then we must
increase ΔF508-CFTR ER export efficiency by ca. 60-fold.
In native expression systems where the ER export efficiency
of wild-type CFTR is ca. 100%, we must potentially increase
ΔF508-CFTR ER export by up to 100-fold. Facilitating
ΔF508-CFTR export by growth of cells at reduced tem-
perature suggests that even when ΔF508-CFTR reaches the
plasma membrane it is still dysfunctional. Open probability
estimates argue that ΔF508-CFTR has a Po ca. 10-fold less
than wild-type CFTR [130], arguing that we may need to
increase rates of biosynthetic insertion of ΔF508-CFTR into
the plasma membrane to 10-fold above the rate for wild-type
CFTR. One way of overcoming the problem of decreased
channel activity is to treat CF patients with a CFTR
“potentiator”. CFTR potentiators are molecules that have
little or no impact upon the trafficking defects of mutant
CFTR, but are capable of increasing the open probability of
mutant channels [131–134]. Indeed one such compound,
identified by Vertex Pharmaceuticals (VX-770) using a high
throughput screening (HTS) approach, has recently entered
Phase 1 clinical trials for the treatment of CF patients. It is
11N. Ameen et al. / Journal of Cystic Fibrosis 6 (2007) 1–14unlikely that potentiators alone will yield an effective therapy
for patients bearing the ΔF508 mutation, since potentiators
rely on being able to increase the activity of channels that are
already present in the plasma membrane. Thus, a combina-
tion of drugs acting on both channel activity (potentiators)
and protein folding (correctors) will probably need to be
utilized. However, such therapies rely on retaining mutant
CFTR molecules within the plasma membrane. Once in the
plasma membrane,ΔF508-CFTR has a significantly reduced
stability compared to wild-type CFTR; due to an inability of
ΔF508-CFTR to recycle properly. Whether a single drug will
be able to facilitate ΔF508 exit from the ER and enhance
ΔF508 recycling is debatable. Perhaps a combination of
drugs targeted at different aspects of ΔF508 trafficking will
be required to provide therapeutic benefit. Although ΔF508
is by far the most common mutation in CFTR, there are many
hundreds of other mutations described, the trafficking
consequences of which have not been evaluated. For
example, there is nothing known about the trafficking of
G551D CFTR, a mutation common in Scottish and
Scandinavian populations. Nevertheless, as we begin to
unravel the mysteries and intricacies of CFTR's endocytic
travels, we are likely to come across important new
pharmacological targets for maintaining cell surface CFTR.
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